NovoCure (NVCR) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free NVCR Stock Alerts $12.64 +0.40 (+3.27%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNovoCure Limited (NASDAQ:NVCR) Shares Purchased by C WorldWide Group Holding A Smarketbeat.com - April 27 at 5:21 PMFederated Hermes Inc. Has $9.21 Million Position in NovoCure Limited (NASDAQ:NVCR)marketbeat.com - April 25 at 5:33 AMNovoCure (NASDAQ:NVCR) Share Price Passes Below 50 Day Moving Average of $14.57americanbankingnews.com - April 25 at 4:44 AMNovoCure (NVCR) Scheduled to Post Earnings on Thursdayamericanbankingnews.com - April 25 at 1:28 AMResults of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024finance.yahoo.com - April 24 at 3:27 PMResults of Novocure's METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024businesswire.com - April 24 at 10:45 AMBuy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Executionmarkets.businessinsider.com - April 11 at 10:38 AMNovoCure (NASDAQ:NVCR) Given "Overweight" Rating at Piper Sandlermarketbeat.com - April 10 at 9:19 AMBaillie Gifford & Co. Sells 1,974,073 Shares of NovoCure Limited (NASDAQ:NVCR)marketbeat.com - April 10 at 8:34 AMNovoCure (NASDAQ:NVCR) Trading 4.9% Higher marketbeat.com - April 9 at 11:45 AMNovocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024businesswire.com - April 5 at 7:00 AMNovoCure (NASDAQ:NVCR) Shares Gap Down Following Analyst Downgrademarketbeat.com - April 3 at 1:36 PMWells Fargo & Company Lowers NovoCure (NASDAQ:NVCR) Price Target to $42.00marketbeat.com - April 3 at 1:35 PMNovoCure (NVCR) Receives a Buy from Wells Fargomarkets.businessinsider.com - April 3 at 1:35 AMNovoCure (NASDAQ:NVCR) Shares Down 6.6% marketbeat.com - April 2 at 3:17 PMNovocure to Report First Quarter 2024 Financial Resultsfinance.yahoo.com - April 1 at 10:35 AMQ4 2025 EPS Estimates for NovoCure Limited (NASDAQ:NVCR) Cut by Analystmarketbeat.com - March 31 at 1:48 AMWhy NovoCure Stock Soared 18.3% This Weekfool.com - March 30 at 6:34 AMNovoCure’s TTFields Show Promise in METIS Study: Outperform Rating Reaffirmed with Raised Price Targetmarkets.businessinsider.com - March 29 at 10:34 AMBrokers Offer Predictions for NovoCure Limited's Q4 2025 Earnings (NASDAQ:NVCR)marketbeat.com - March 29 at 9:25 AMWhy Novocure Stock Is Jumping Todayfool.com - March 28 at 11:50 AMNovoCure (NASDAQ:NVCR) Trading Up 4.8% Following Analyst Upgrademarketbeat.com - March 28 at 10:31 AMNovoCure: Sell The METIS-Inspired Rallyseekingalpha.com - March 27 at 10:55 PMNovoCure's (NVCR) Neutral Rating Reiterated at Wedbushmarketbeat.com - March 27 at 10:10 PMNuanced Phase 3 Results Prompt Cautious Hold Rating for NovoCure’s Stockmarkets.businessinsider.com - March 27 at 8:12 PMNovocure's device shown to slow cancer progression in the brain in trialmsn.com - March 27 at 8:12 PMPeeling Back The Layers: Exploring NovoCure Through Analyst Insightsmarkets.businessinsider.com - March 27 at 8:12 PMNovocure’s stock surges after positive results in brain-cancer trialmarketwatch.com - March 27 at 3:12 PMNovocure Shares Rise After Phase 3 METIS Trial Met Primary Endpointmarkets.businessinsider.com - March 27 at 3:12 PMNovocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Showsmsn.com - March 27 at 3:12 PMNovoCure (NASDAQ:NVCR) Price Target Raised to $24.00 at HC Wainwrightmarketbeat.com - March 27 at 2:13 PMNovoCure (NASDAQ:NVCR) Shares Gap Up to $13.07marketbeat.com - March 27 at 11:47 AMNovoCure device slows spread of lung cancer to brain in late-stage study; shares riseproactiveinvestors.com - March 27 at 11:00 AMNovocure Shares Surge Premarket on Phase 3 TTFields Studymarketwatch.com - March 27 at 10:11 AMNovocure shares jump after trial meets primary endpointinvesting.com - March 27 at 10:11 AMNovocure's lung cancer therapy succeeds in late-stage trialmsn.com - March 27 at 10:11 AMmarketbeat.com - March 27 at 9:41 AMZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancerbusinesswire.com - March 27 at 9:29 AMMETIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancerbusinesswire.com - March 27 at 7:00 AMNovoCure (NASDAQ:NVCR) Trading Down 6%marketbeat.com - March 22 at 5:06 PMNovoCure (NASDAQ:NVCR) Price Target Raised to $17.00marketbeat.com - March 20 at 10:39 AMNVCR Dec 2025 17.500 callfinance.yahoo.com - March 20 at 5:21 AMNVCR Jan 2026 20.000 callfinance.yahoo.com - March 20 at 5:21 AMNVCR Apr 2024 10.000 putfinance.yahoo.com - March 15 at 8:59 PMNVCR Apr 2024 17.500 callfinance.yahoo.com - March 15 at 8:59 PMNovoCure’s Clinical Trial Results: Subgroup Promise Amidst Cautioned Market Outlookmarkets.businessinsider.com - March 12 at 8:11 PMNovoCure (NASDAQ:NVCR) Shares Down 3.9% marketbeat.com - March 12 at 12:53 PMINNOVATE-3 Late Breaking Abstract Selected as a Best Oral Presentation at ESGObusinesswire.com - March 11 at 7:00 AMNovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of "Moderate Buy" from Analystsmarketbeat.com - March 11 at 2:32 AMSeven Eight Capital LP Acquires 71,989 Shares of NovoCure Limited (NASDAQ:NVCR)marketbeat.com - March 6 at 9:50 AM Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. NVCR Media Mentions By Week NVCR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NVCR News Sentiment▼0.070.32▲Average Medical News Sentiment NVCR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NVCR Articles This Week▼75▲NVCR Articles Average Week Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LeMaitre Vascular News AtriCure News MiMedx Group News Alphatec News Artivion News Paragon 28 News Atrion News OrthoPediatrics News Treace Medical Concepts News Silk Road Medical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NVCR) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressProtect Your Bank Account Before It’s Too LateWeiss RatingsJeff Bezos Just Humiliated Elon MuskInvestorPlace4 Cryptos BETTER than BitcoinTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
